We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-17.58%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$221M
AUM Growth
-$96.8M
Cap. Flow
-$24.3M
Cap. Flow %
-11.03%
Top 10 Hldgs %
60.19%
Holding
74
New
20
Increased
14
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
HOLX
Hologic
HOLX
+$22.6M
2
SNY icon
Sanofi
SNY
+$19.6M
3
PFE icon
Pfizer
PFE
+$18.3M
4
SIBN icon
SI-BONE Inc
SIBN
+$15.6M
5
JNJ icon
Johnson & Johnson
JNJ
+$6.88M

Top Sells

Rank Stock Value
1
COR icon
Cencora
COR
+$18.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$16.2M
3
LH icon
Labcorp
LH
+$13.7M
4
ELV icon
Elevance Health
ELV
+$10.5M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.6%
2 Industrials 2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
51
CALL
Aclaris Therapeutics
ACRS
$869M
– –
-376,200
Closed -$94K
ADVM
52
DELISTED
Adverum Biotechnologies
ADVM
– –
-21,482
Closed -$2.48M
APLS
53
DELISTED
Apellis Pharmaceuticals
APLS
– –
-19,362
Closed -$593K
ATNM icon
54
Actinium Pharmaceuticals
ATNM
$25M
– –
-22,570
Closed -$147K
BAX icon
55
Baxter International
BAX
$14.2B
– –
-34,151
Closed -$2.86M
CNMD icon
56
CONMED
CNMD
$1.47B
– –
-17,940
Closed -$2.01M
COR icon
57
Cencora
COR
$61.2B
– –
-218,820
Closed -$18.6M
EVH icon
58
Evolent Health
EVH
$447M
– –
-597,303
Closed -$5.41M
IRTC icon
59
iRhythm Holdings
IRTC
$4.2B
– –
-89,614
Closed -$6.1M
LQDA icon
60
Liquidia Corp
LQDA
$8.02B
– –
-317,993
Closed -$1.36M
NCNA
61
NuCana
NCNA
$6.12M
– –
-22
Closed -$666K
REGN icon
62
Regeneron Pharmaceuticals
REGN
$80.8B
– –
-27,390
Closed -$10.3M
SPY icon
63
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$823B
– –
-16,600
Closed -$5.34M
SRPT icon
64
Sarepta Therapeutics
SRPT
$1.77B
– –
-39,822
Closed -$5.14M
STRO icon
65
Sutro Biopharma
STRO
$421M
– –
-3,267
Closed -$359K
TNDM icon
66
Tandem Diabetes Care
TNDM
$1.56B
– –
-21,361
Closed -$1.27M
KA
67
CALL
DELISTED
Kineta, Inc. Common Stock
KA
– –
-339
Closed -$108K
SILK
68
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-51,303
Closed -$2.07M
MDRX
69
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-447,986
Closed -$4.4M
SDC
70
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
– –
-59,178
Closed -$517K
DRNA
71
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-13,768
Closed -$303K
WMGI
72
DELISTED
Wright Medical Group Inc
WMGI
– –
-11,669
Closed -$356K
1 2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Endurant Capital Management held 74 positions worth $221M, down 30% from $317M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Endurant Capital Management withdrew a net $24.3M in Q1 2020, closing 23 positions and reducing 17 holdings. Its most notable exit was Cencora, an estimated $18.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Industrials.

Against the trend, Endurant Capital Management opened a new position in Hologic worth $16.6M.

  • Endurant Capital Management's largest Q1 2020 buy was Hologic: 473,667 shares worth $16.6M.
  • Endurant Capital Management added most to SI-BONE Inc in Q1 2020, an estimated $15.6M increase.
  • Endurant Capital Management's biggest Q1 2020 reduction was Bristol-Myers Squibb, cutting an estimated $16.2M.
  • Endurant Capital Management fully exited Cencora in Q1 2020, selling an estimated $18.6M.
  • Endurant Capital Management's ten largest holdings make up 60% of its $221M portfolio in Q1 2020.
  • Endurant Capital Management opened 20 new positions and closed 23 in Q1 2020.
  • Endurant Capital Management's portfolio value fell 30% quarter-over-quarter to $221M.

Based on Endurant Capital Management's 13F filing for Q1 2020, filed 15 May 2020.